Key result
Sophocarpine attenuates diabetes-induced cardiac dysfunction in mice by suppressing NF-κB signaling.
Why the study?
Diabetic cardiomyopathy is a leading cause of mortality in patients with diabetes, prompting investigation into whether sophocarpine could protect against it.
Does sophocarpine protect against diabetic cardiomyopathy in preclinical models?
Population
Hyperglycemic myocardial cells and a streptozotocin-induced type 1 diabetes mellitus mouse model
Comparison
Sophocarpine treatment
Design
In vitro and in vivo preclinical study
Authors
Loading...
No immediate clinical implications; hypothesis-generating for sophocarpine in diabetic cardiomyopathy and requires human translation studies.
Does sophocarpine protect against diabetic cardiomyopathy in preclinical models?
p-value: p=<0.05
Sophocarpine demonstrates protective effects against diabetic cardiomyopathy in preclinical models by suppressing NF-κB-mediated inflammation.
Zou et al. (2019) studied Diabetic cardiomyopathy (n=40). Sophocarpine vs. PBS (vehicle) was evaluated on Cardiac function (LVEF, FS, LVEDD, LVESD, E/A ratio) and structural remodeling (p=<0.05). Sophocarpine significantly attenuated diabetes-induced cardiac dysfunction, remodeling, inflammation, and apoptosis in a mouse model of diabetic cardiomyopathy by suppressing the NF-κB signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: